Enterprise Value

-105M

Cash

386.9M

Avg Qtr Burn

-45.59M

Short % of Float

34.76%

Insider Ownership

36.80%

Institutional Own.

57.18%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Imvotamab (IGM-2323) (CD20 x CD3) Details
Autoimmune disease, Systemic lupus erythematosus

Phase 1b

Initiation

Imvotamab (IGM-2323) (CD20 x CD3) Details
Autoimmune disease, Rheumatoid arthritis

Phase 1b

Initiation

Phase 1

Data readout

IGM-7354 (IL-15 x PD-L1) Details
Solid tumor/s, Cancer, Hematologic malignancies

Phase 1

Update

Phase 1

Update

Phase 1

Update

Aplitabart (IGM-8444) + birinapant Details
Solid tumor/s, Hematologic malignancies

Phase 1

Update

Imvotamab (IGM-2323) (CD20 x CD3) Details
Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia

Failed

Discontinued

IGM-6268 Details
Solid tumor/s, Cancer

Failed

Discontinued